December, 2004:

Study: doctors switching from suspect painkillers

Sanofi-Aventis to cut sales and marketing posts in N.J.

Genentech restructures BioOncology, hematology with hires

Corbett Accel names Kelly to head N.Y. shop

FDA issues COX-2, NSAID public health advisory

FDA calls Crestor ads ‘false and misleading’

Nabi names new senior vice president, global sales and marketing

Bush administration says importation does not equal savings

Schering names Pfizer alumna to global comms post

Naproxen fourth painkiller linked to heart risk

CMI promotes Davis to media account supervisor

Biovail’s Ralivia receives approvable letter

Pfizer halts DTC ads for Celebrex

AstraZeneca’s cancer drug Iressa fails in trial

Pfizer reports Celebrex heart risk

MD Net Guide adds new title

Ascend acquires Medical World

$60 million to be spent on DTC ads for Sepracor sleep drug

Four promoted at IMNG

PhRMA taps Tauzin for top post

Merck to cut 5,100 jobs by year’s end

Bristol-Myers Squibb sells Oncology Therapeutics Network

Nordstrom to succeed Torre as McCann Healthcare chief executive

BMS to ask FDA to sell Pravachol without a prescription

Research suggests that not all COX-2 drugs are the same

Thompson bemoans policy on drug costs and safety

AMP to host special event focusing on journal advertising

AMA resolution calls for sharing of drug trial info

JAMA editors call for new FDA monitoring office

Lilly chief exec affirms company is not for sale

HBA names new president, executive committee members

Lilly offers upbeat 2005 outlook

Merck begins investigation into its handling of Vioxx

Research suggests Celebrex risk lower than Vioxx

Eisen named president of Corbett Accel-Chicago

Pfizer seeks approval for new Viagra use

Saatchi reportedly wins Levitra DTC work

InChord acquires U.K. based advertising agency

Pfizer expects patent losses to hurt bottom line